PLM 102
Alternative Names: PLD-102; PLM-102Latest Information Update: 20 Jun 2025
At a glance
- Originator PeLeMed
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Proto-oncogene protein c-ret modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical study in Acute myeloid leukemia presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 20 Feb 2025 Phase-I clinical trials in Acute myeloid leukaemia in South Korea (PO), prior to February 2025 (PeLeMed pipeline, February 2025)
- 14 Apr 2023 Pharmacodynamics and pharmacokinetics data from a preclinical study in Acute myeloid leukemia presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)